Pan-cancer characterization of cell-free immune-related miRNA identified as a robust biomarker for cancer diagnosis
Authors (first, second and last of 15)
Collection
Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
Liquid biopsies rely upon detection of circulating tumor cells, cell free DNA, RNA, proteins, lipids, and metabolites present in biofluids of patients. These biospecimens can be easily and reproducibly collected for analyses. The rapid advances in sequencing technologies have further helped the development of FDA-approved liquid biopsies companion diagnostic tests used by clinicians.
This special issue published by Molecular Cancer focuses on the clinical aspects of liquid biopsies, in particular validation of novel biomarkers that may serve as signature for non-invasive early detection of cancerous cells, predict patients' risks of disease progression and response to specific therapies.
Articles (19 in this collection)
-
-
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles
Authors (first, second and last of 12)
-
Significant CircRNAs in liver cancer stem cell exosomes: mediator of malignant propagation in liver cancer?
Authors (first, second and last of 9)
-
Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis
Authors (first, second and last of 26)
-
A circulating cell-free DNA methylation signature for the detection of hepatocellular carcinoma
Authors (first, second and last of 19)
-
BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours
Authors (first, second and last of 17)
-
A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triple-negative breast cancer
Authors (first, second and last of 12)
-
Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application
Authors (first, second and last of 7)
-
Recent advances of small extracellular vesicle biomarkers in breast cancer diagnosis and prognosis
Authors (first, second and last of 6)
-
-
Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma
Authors (first, second and last of 20)
-
A novel polypeptide encoded by the circular RNA ZKSCAN1 suppresses HCC via degradation of mTOR
Authors (first, second and last of 17)
-
Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance
Authors (first, second and last of 6)
-
A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer
Authors (first, second and last of 12)
-
Clinical application and detection techniques of liquid biopsy in gastric cancer
Authors (first, second and last of 9)
-
An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer
Authors (first, second and last of 11)
-
A liquid biopsy signature of circulating exosome-derived mRNAs, miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer
Authors (first, second and last of 10)
-
BTApep-TAT peptide inhibits ADP-ribosylation of BORIS to induce DNA damage in cancer
Authors (first, second and last of 9)
-
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection
Authors (first, second and last of 32)
